Revenue for the quarter totaled $541,106 compared to $292,015 in
the prior year’s second quarter ended December 31, 2004, which
represents an 85% increase. The Company incurred a net loss of $283,927
for the quarter or $(.01) per share compared with a net loss of $439,768
for the prior year’s quarter or $(.02) per share. Total tests
transmitted, a key metric for gauging customer usage, was 7,660 for the
quarter, a 63% increase from the prior year’s quarterly transmissions.
For the six month period ended December 31, 2005, total revenue was
$922,022, compared to $545,436 for the same period one year ago, a 69%
increase. For the six month period ended December 31, 2005, the Company
incurred a net loss of $621,144, or $(.02) per share, compared with a
net loss of $874,247, or $(.03) per share, for the same period one year
ago.
“This was a pivotal quarter for the Company,” commented CEO Mark
Schwartz. “We are beginning to see the results of our team’s hard work
and the market’s acceptance of our technology,” added Mr. Schwartz.
The Company has scheduled a conference call to discuss its quarterly
financial results on Tuesday, February 14th, at 4:00 PM Central Time.
Please contact the Company at 888-687-9999 x106 for conference call
information.
Forward-looking statements in this press release are made under the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The Company wishes to caution readers not to place undue reliance
on any forward-looking statements and to recognize that the statements
are not a prediction of actual future results. Actual results could
differ materially from those presented and anticipated in the
forward-looking statements due to the risks and uncertainties set forth
in the Company’s 2005 Annual Report on Form 10-KSB, and subsequent
Quarterly Reports on 10-QSB, all of which were filed with the U.S.
Securities and Exchange Commission, as well as others not now
anticipated.
View PDF
file:
Second Quarter FY
2006 Results
CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are
trademarks of Hypertension Diagnostics, Inc. All
rights reserved.
Website: www.HDII.com
Contact: Mark Schwartz, CEO
651-687-9999